Katherine Y. King, MD, PhD

Katherine Y. King MD PhD is Professor of Pediatric Infectious Diseases at Baylor College of Medicine and Texas Children’s Hospital, where she is part of the faculty for the Stem Cells and Regenerative Medicine Center and serves as Co-Director of the BCM Medical Scientist Training Program. A board-certified pediatric infectious diseases physician, Dr. King assists in the diagnosis and treatment of infections and suspected infections in children of all ages with an evidence-based approach. Her research focuses on the molecular mechanisms by which inflammation affects blood and immune cell production and clonal competition by hematopoietic stem cells in the bone marrow.

Dr. King has been the recipient of the National Heart, Lung, and Blood Institute R35 Emerging Investigator Award and the Presidential Early Career Award for Scientists and Engineers (PECASE). She is a member of the Society for Pediatric Research, the American Pediatric Society, and the American Society for Clinical Investigation. She serves on the Board of the International Society for Experimental Hematology.

Personal Statement

I am a native Houstonian and honored to be involved in the care and treatment of children in this community.

Clinical Interests

General pediatric infectious disease, antibiotic-associated neutropenia

Education

Organizations

Board Certification

American Board of Pediatrics in Pediatric Infectious Diseases

Honors and awards

2022

DeBakey Research Award, Baylor College of Medicine 

2022

Research Mentor Award, Texas Children’s Hospital

2021

R35 Emerging Investigator Award National Heart, Lung, and Blood Institute 

2019

Presidential Early Career Award for Scientist and Engineers, National Science Foundation

2007

Chief Resident, Baylor College of Medicine

* Texas Children’s Hospital physicians’ licenses and credentials are reviewed prior to practicing at any of our facilities. Sections titled From the Doctor, Professional Organizations and Publications were provided by the physician’s office and were not verified by Texas Children’s Hospital.

Research interests

Impact of infection and inflammation on bone marrow function, role of the microbiome in steady state hematopoiesis, environmental drivers of clonal hematopoiesis

Kain BN, Tran BT, Luna PN, Cao R, Le DT, Florez MA, Maneix L, Toups JD, Morales-Mantilla DE, Koh S, Han H, Jaksik R, Huang Y, Catic A, Shaw CA, King KY. Hematopoietic stem and progenitor cells confer cross-protective trained immunity in mouse models. iScience, 2023, 26(9):107596. PMID 37664586

Le DT, Florez MA, Kus P, Tran BT, Kain B, Zhu Y, Christensen K, Jain A, Malovannaya A, and King KY. BATF2 promotes HSC myeloid differentiation by amplifying IFN response mediators during chronic infection. iScience, 2023, 26(2):106059 PMID:36824275

Yan H, Walker FC, Ali A, Han H, Tan L, Veillon L, Lorenzi PL, Baldridge MT, and King KY. The bacterial microbiota regulates normal hematopoiesis via metabolite-induced type 1 interferon signaling. Blood Advances, 2022, 6(6):1754-65. PMID: 35143611

Morales-Mantilla DE, Kain B, Le D, Flores AR, Paust S, and King KY. Hematopoietic stem and progenitor cells improve survival from sepsis by boosting immunomodulatory cells. eLife, 2022, 11:e74561. PMID: 35166205

Hormaechea-Agulla D, Matatall K, Le DT, Kain B, Long X, Kus P, Jaksik R, Challen GA, Kimmel M, and King KY. Chronic infection drives Dnmt3a-loss of function clonal hematopoiesis via IFNg signaling. Cell Stem Cell, 2021, 28(8):1428-1442. PMID: 33743191

Florez M, Matatall KA, Jeong Y, Ortinau L, Shafer P, Lynch A, Jaksik R, Kimmel M, Park D, and King KY. IFNg mediates hematopoietic stem cell activation and niche relocalization through BST2. Cell Reports, 2020, 33(12):108530. PMID: 33357430

Josefsdottir KS, Baldridge MT, Kadmon CS, and King KY. Antibiotics impair murine hematopoiesis by depleting intestinal microbiota. Blood, 2017, 129(6):729-739. PMID: 27879260

View VIICTR Publications

View PubMed Publications

View Google Scholar Publications